<DOC>
	<DOCNO>NCT00836914</DOCNO>
	<brief_summary>The purpose study determine safety effect CAL-101 subject allergic rhinitis .</brief_summary>
	<brief_title>Study Investigate Effects CAL-101 Subjects With Allergic Rhinitis Exposed Allergen Environmental Chamber</brief_title>
	<detailed_description>A Phase I , randomize , double-blind crossover study CAL-101 , oral inhibitor phosphatidylinositol 3-kinase ( PI3K ) delta , patient allergic rhinitis .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>1 . Age &gt; = 18 &lt; = 55 year 2 . Has history seasonal allergic rhinitis least 2 year 3 . Has sensitivity grass pollen demonstrate positive response skin prick test 4 . Has positive Radio Allergen Sorbent Test ( &gt; = class 2 ) grass pollen previous 12 month screen 5 . Is otherwise healthy , , free clinically significant illness disease determine medical history , physical examination laboratory test , include normal 12lead electrocardiogram ( ECG ) 6 . Has condition would make subject unlikely able remain allergen challenge chamber 4 hour 7 . Is available complete study procedure 8 . Is able provide write informed consent , include compliance requirement restriction list consent form 1 . Is female childbearing potential ( nonchildbearing potential mean document surgery result infertility postmenopausal menses least 1 year ) 2 . History chronic nasal upper respiratory tract symptoms disorder allergic rhinitis 3 . History nonallergic rhinitis , chronic sinusitis severe asthma 4 . Has nasal condition likely affect outcome study , i.e . nasal septal perforation , nasal polyp , sinus disease , chronic nasal obstruction , nasal diseases 5 . Is currently take regular medication , whether prescribe , include corticosteroid , vitamin , macrolides , antifungal agent herbal remedy , e.g . St. John 's Wort . Paracetamol ( &lt; = 2g/day ) need use shortacting B2agonists allow . 6 . Has take prohibit medication within specify interval prior Visit 1 : Corticosteroids ( depot , 90 day ; systemic , 30 day ; dermatologic 14 day ) Chromones ( 14 day ) Antihistamines ( nasal longacting oral , 10 day ; shortingacting oral , 2 day ; ocular , 3 day ) Decongestants ( 3 day ) Leukotriene modifier ( 10 day ) Anticholinergics ( 7 day ) Opthalmic nonsteroidal antiinflammatory drug ( 3 day ) Nasalophthalmic wash solution ( 12 hr ) Immunotherapy ( 12 hr ) 7 . Is currently treat medication induces inhibit cytochrome P450 ( CYP ) 3A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Phosphatidylinositol 3-kinase</keyword>
</DOC>